MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has announced that its Life Science business sector is investing more than $286 million in its biosafety testing capacity at the company’s site in Rockville, Maryland, USA.
MilliporeSigma is investing $65 million to expand its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, WI. The investment will allow large-scale manufacturing of increasingly potent compounds that have the potential to treat cancer. Completion is expected by mid-2022 and should add approximately 50 full-time jobs starting in 2021.
Palantir to offer cancer analytics under JV deal with Germany`s Merck
Merck’s vaccines powered ahead to start the year, helping the drug giant offset other areas of weakness on the way to slight growth overall. Led by HPV vaccine franchise Gardasil and pneumococcal shot Pneumovax 23, Merck’s vaccine sales grew 21% in the first quarter to $1.5 billion.
Merck has divested its biosimilars business to fellow German drugmaker Fresenius in a deal potentially worth 670 million euros.
Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in sterile generics as well as in the rapidly expanding area of biosimilars.
Merck KGaA said it is developing a children's formula of its drug to treat schistosomiasis, a parasitic worm disease that infects millions of poor people in Africa and Asia.
Merck KGaA spinoff Calypso Biotech has licensed its inflammatory bowel disease candidate to EA Pharma, a joint venture between Eisai and Ajinomoto. The agreement gives EA Pharma the global license to anti-MMP-9 monoclonal antibody CALY-001.
Roche surprised industry watchers on Tuesday when it placed a $65,000 list price on multiple sclerosis blockbuster-to-be Ocrevus, sparking comparisons with a more expensive—and less effective, according to trial data—Merck KGaA rival. But it's a comparison the German drugmaker doesn't much care for.
Merck has signed a collaboration agreement with the UK’s Avillion under which the latter will develop the German drug giant’s anti IL-17 A/F Nanobody as a treatment for plaque psoriasis.